Guggenheim Capital LLC Grows Stock Position in Boston Scientific Co. (NYSE:BSX)

Guggenheim Capital LLC boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 118,191 shares of the medical equipment provider's stock after buying an additional 6,882 shares during the period. Guggenheim Capital LLC's holdings in Boston Scientific were worth $10,557,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BSX. TFC Financial Management Inc. lifted its stake in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Global Wealth Strategies & Associates grew its holdings in shares of Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC purchased a new stake in Boston Scientific during the 4th quarter valued at about $29,000. Valley National Advisers Inc. raised its stake in shares of Boston Scientific by 262.4% during the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 286 shares during the last quarter. Finally, Fairway Wealth LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth about $36,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares in the company, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Daniel J. Brennan sold 15,087 shares of the business's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the transaction, the chief financial officer now owns 241,451 shares of the company's stock, valued at approximately $25,369,256.57. This represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 133,183 shares of company stock valued at $13,948,476. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on BSX shares. Truist Financial reduced their target price on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Piper Sandler lifted their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Stifel Nicolaus raised their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Friday, January 10th. Finally, StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $110.22.

Boston Scientific Stock Up 1.5 %

Shares of NYSE:BSX traded up $1.39 on Tuesday, reaching $94.97. The company had a trading volume of 1,809,349 shares, compared to its average volume of 6,366,446. Boston Scientific Co. has a 52-week low of $66.80 and a 52-week high of $107.17. The firm's 50 day simple moving average is $99.22 and its 200-day simple moving average is $94.54. The firm has a market capitalization of $140.46 billion, a PE ratio of 76.07, a PEG ratio of 2.79 and a beta of 0.73. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.